Cervical cancers harbor high rates of potentially targetable oncogenic mutations. In addition, squamous cell carcinoma and adenocarcinoma of the cervix have distinct molecular treatment strategies profiles, suggesting that clinical outcomes may be improved with the use of more tailored treatment strategies, including PI3K and MEK inhibitors.
CITATION STYLE
Wright, A. A., Howitt, B. E., Myers, A. P., Dahlberg, S. E., Palescandolo, E., Van Hummelen, P., … Hirsch, M. S. (2013). Oncogenic mutations in cervical cancer. Cancer, 119(21), 3776–3783. https://doi.org/10.1002/cncr.28288
Mendeley helps you to discover research relevant for your work.